X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs WOCKHARDT LTD. - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS WOCKHARDT LTD. IPCA LABS/
WOCKHARDT LTD.
 
P/E (TTM) x 29.1 -18.4 - View Chart
P/BV x 3.7 2.0 189.6% View Chart
Dividend Yield % 0.1 0.0 6,415.1%  

Financials

 IPCA LABS   WOCKHARDT LTD.
EQUITY SHARE DATA
    IPCA LABS
Mar-18
WOCKHARDT LTD.
Mar-18
IPCA LABS/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs6951,012 68.7%   
Low Rs400532 75.3%   
Sales per share (Unadj.) Rs260.2355.9 73.1%  
Earnings per share (Unadj.) Rs19.0-60.3 -31.5%  
Cash flow per share (Unadj.) Rs33.1-46.8 -70.7%  
Dividends per share (Unadj.) Rs1.000.01 10,000.0%  
Dividend yield (eoy) %0.20 14,090.7%  
Book value per share (Unadj.) Rs213.0257.8 82.6%  
Shares outstanding (eoy) m126.20110.63 114.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.12.2 97.1%   
Avg P/E ratio x28.9-12.8 -225.5%  
P/CF ratio (eoy) x16.6-16.5 -100.4%  
Price / Book Value ratio x2.63.0 85.9%  
Dividend payout %5.30 -31,772.7%   
Avg Mkt Cap Rs m69,12085,379 81.0%   
No. of employees `00013.36.3 211.9%   
Total wages/salary Rs m7,3599,371 78.5%   
Avg. sales/employee Rs Th2,477.46,295.0 39.4%   
Avg. wages/employee Rs Th555.21,498.3 37.1%   
Avg. net profit/employee Rs Th180.6-1,066.3 -16.9%   
INCOME DATA
Net Sales Rs m32,83639,369 83.4%  
Other income Rs m4181,202 34.8%   
Total revenues Rs m33,25440,571 82.0%   
Gross profit Rs m4,50518 24,616.4%  
Depreciation Rs m1,7771,495 118.9%   
Interest Rs m2402,555 9.4%   
Profit before tax Rs m2,905-2,830 -102.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m511257 198.9%   
Profit after tax Rs m2,394-6,669 -35.9%  
Gross profit margin %13.70 29,514.3%  
Effective tax rate %17.6-9.1 -193.7%   
Net profit margin %7.3-16.9 -43.0%  
BALANCE SHEET DATA
Current assets Rs m19,45533,796 57.6%   
Current liabilities Rs m10,07626,917 37.4%   
Net working cap to sales %28.617.5 163.5%  
Current ratio x1.91.3 153.8%  
Inventory Days Days9879 123.4%  
Debtors Days Days6789 75.0%  
Net fixed assets Rs m20,26039,664 51.1%   
Share capital Rs m252553 45.6%   
"Free" reserves Rs m26,63327,968 95.2%   
Net worth Rs m26,88628,522 94.3%   
Long term debt Rs m2,34021,731 10.8%   
Total assets Rs m41,17381,620 50.4%  
Interest coverage x13.1-0.1 -12,179.6%   
Debt to equity ratio x0.10.8 11.4%  
Sales to assets ratio x0.80.5 165.3%   
Return on assets %6.4-5.0 -127.0%  
Return on equity %8.9-23.4 -38.1%  
Return on capital %10.8-7.7 -140.2%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,6429,807 159.5%   
Fx outflow Rs m4,8841,789 273.0%   
Net fx Rs m10,7598,019 134.2%   
CASH FLOW
From Operations Rs m3,411684 498.4%  
From Investments Rs m-1,3546,302 -21.5%  
From Financial Activity Rs m-1,304-7,695 16.9%  
Net Cashflow Rs m753-664 -113.4%  

Share Holding

Indian Promoters % 45.9 74.5 61.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 2.3 495.7%  
FIIs % 25.3 7.7 328.6%  
ADR/GDR % 0.0 0.1 -  
Free float % 17.4 15.4 113.0%  
Shareholders   36,892 67,757 54.4%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Dec 12, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS